5 Best Performing Growth Stocks So Far in 2026

4. ImmunityBio, Inc. (NASDAQ:IBRX)

Year-Over-Year Revenue Growth: 351.53%

Year-to-Date Performance: 242.57%

Number of Hedge Fund Holders: 25

ImmunityBio, Inc. (NASDAQ:IBRX) ranks among the best-performing growth stocks so far in 2026. On June 1, ImmunityBio, Inc. (NASDAQ:IBRX) reported that it presented two research posters and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held from May 29 to June 2, 2026, in Chicago.

The presentations included results from two randomized Phase 3 trials in advanced non-small cell lung cancer (NSCLC) and a matched adjusted indirect comparison (MAIC) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The presentations evaluated ANKTIVA (nogapendekin alfa inbakicept-pmln), the company’s IL-15 receptor agonist immunotherapy, which is designed to activate natural killer (NK) cells, CD4+ and CD8+ T cells, and memory T cells across different solid tumor types.

According to the report by ImmunityBio, Inc. (NASDAQ:IBRX), ANKTIVA is the first FDA-approved immunotherapy created to stimulate these important immune cells, which are depleted in patients with lymphopenia and play a key role in fighting cancer.

Growing long-term survival data across bladder, lung and other solid tumors support the idea that restoring immune competence and treating lymphopenia could become an important part of cancer care. The company believes these findings highlight the potential of activating and amplifying the immune system rather than suppressing it.

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company that is focused on developing and commercializing next-generation immunotherapies for cancer and infectious diseases.

1281292 - 11759070 - 1